Ensysce Biosciences Stock Performance
| ENSC Stock | USD 2.31 0.24 11.59% |
The firm shows a Beta (market volatility) of 1.32, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ensysce Biosciences will likely underperform. At this point, Ensysce Biosciences has a negative expected return of -0.75%. Please make sure to confirm Ensysce Biosciences' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Ensysce Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Ensysce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in June 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 11.59 | Five Day Return 8.96 | Year To Date Return (72.00) | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:15 | Last Split Date 2024-12-06 |
1 | Disposition of 8330 shares by Carrera Eric of Ensysce Biosciences subject to Rule 16b-3 | 02/28/2025 |
2 | Acquisition by Martin Steven Robert of 65850 shares of Ensysce Biosciences at 3.35 subject to Rule 16b-3 | 03/07/2025 |
3 | Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results | 03/10/2025 |
4 | Acquisition by Lynn Kirkpatrick of 263400 shares of Ensysce Biosciences at 3.19 subject to Rule 16b-3 | 03/19/2025 |
5 | Ensysce Biosciences corrects SEC filing omission - Investing.com | 04/01/2025 |
6 | Ensysce Biosciences Concludes Key Phase in PF614-MPAR Overdose Protection Study ENSC ... | 04/15/2025 |
7 | Ensysce Biosciences Plans to Sell Over 650,000 Shares | 04/16/2025 |
8 | Ensysce Biosciences, Inc. Announces Exercise of Warrants for 2.2 Million Gross Proceeds | 04/23/2025 |
9 | Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for 2. ... | 04/24/2025 |
10 | Press Release Distribution PR Platform - ACCESS Newswire | 04/25/2025 |
11 | Is it time to hedge Ensysce Biosciences high volatility | 04/28/2025 |
12 | Ensysce Biosciences Bolsters Management Team with Regulatory Expert ENSC Stock News | 05/12/2025 |
13 | ENSC is Moving Closer to Changing the Pain Relief Market | 05/14/2025 |
| Begin Period Cash Flow | 1.1 T |
Ensysce Biosciences Relative Risk vs. Return Landscape
If you would invest 580.00 in Ensysce Biosciences on February 14, 2025 and sell it today you would lose (349.00) from holding Ensysce Biosciences or give up 60.17% of portfolio value over 90 days. Ensysce Biosciences is currently does not generate positive expected returns and assumes 14.2208% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Ensysce, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ensysce Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ensysce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ensysce Biosciences, and traders can use it to determine the average amount a Ensysce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0531
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENSC |
Estimated Market Risk
| 14.22 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ensysce Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ensysce Biosciences by adding Ensysce Biosciences to a well-diversified portfolio.
Ensysce Biosciences Fundamentals Growth
Ensysce Stock prices reflect investors' perceptions of the future prospects and financial health of Ensysce Biosciences, and Ensysce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ensysce Stock performance.
| Return On Equity | -5.85 | ||||
| Return On Asset | -1.01 | ||||
| Profit Margin | (1.53) % | ||||
| Operating Margin | (2.74) % | ||||
| Current Valuation | 598.9 K | ||||
| Shares Outstanding | 1.64 M | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 0.73 X | ||||
| Gross Profit | (2.01 M) | ||||
| EBITDA | (6.73 T) | ||||
| Net Income | (7.99 M) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 301.66 K | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | 2.73 X | ||||
| Cash Flow From Operations | (7.5 T) | ||||
| Earnings Per Share | (11.45) X | ||||
| Market Capitalization | 3.8 M | ||||
| Total Asset | 5.6 M | ||||
| Retained Earnings | (129.54 T) | ||||
| Working Capital | 3.14 M | ||||
About Ensysce Biosciences Performance
By analyzing Ensysce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Ensysce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ensysce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ensysce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (5.86) | (6.15) | |
| Return On Tangible Assets | -1.4 M | -1.4 M | |
| Return On Capital Employed | -2 M | -1.9 M | |
| Return On Assets | -1.4 M | -1.4 M | |
| Return On Equity | (2.15) | (2.05) |
Things to note about Ensysce Biosciences performance evaluation
Checking the ongoing alerts about Ensysce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ensysce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ensysce Biosciences generated a negative expected return over the last 90 days | |
| Ensysce Biosciences has high historical volatility and very poor performance | |
| Ensysce Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Ensysce Biosciences currently holds 301.66 K in liabilities with Debt to Equity (D/E) ratio of 6.91, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Ensysce Biosciences has a current ratio of 0.85, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Ensysce Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (2.01 M). | |
| Ensysce Biosciences currently holds about 3.15 M in cash with (7.5 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1. | |
| Latest headline from finance.yahoo.com: ENSC is Moving Closer to Changing the Pain Relief Market |
- Analyzing Ensysce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ensysce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ensysce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ensysce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ensysce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ensysce Biosciences' stock. These opinions can provide insight into Ensysce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |